<VariationArchive VariationID="186518" VariationName="NM_003000.3(SDHB):c.88del (p.Gln30fs)" VariationType="Deletion" Accession="VCV000186518" Version="10" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-07-15" DateCreated="2016-09-24" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="181625" VariationID="186518">
      <GeneList>
        <Gene Symbol="SDHB" FullName="succinate dehydrogenase complex iron sulfur subunit B" GeneID="6390" HGNC_ID="HGNC:10681" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1p36.13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="17018722" stop="17054032" display_start="17018722" display_stop="17054032" Strand="-" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NW_025791756.1" start="1433916" stop="1469227" display_start="1433916" display_stop="1469227" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="17345216" stop="17380664" display_start="17345216" display_stop="17380664" Strand="-" />
          </Location>
          <OMIM>185470</OMIM>
          <Haploinsufficiency last_evaluated="2020-07-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHB">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-07-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHB">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_003000.3(SDHB):c.88del (p.Gln30fs)</Name>
      <CanonicalSPDI>NC_000001.11:17044872:GGG:GG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1p36.13</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="17044873" stop="17044873" display_start="17044873" display_stop="17044873" variantLength="1" positionVCF="17044872" referenceAlleleVCF="TG" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="17371368" stop="17371368" display_start="17371368" display_stop="17371368" variantLength="1" positionVCF="17371367" referenceAlleleVCF="TG" alternateAlleleVCF="T" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.17371370del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.17371370del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.17044875del" Assembly="GRCh38">
            <Expression>NC_000001.11:g.17044875del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012340.1" sequenceAccession="NG_012340" sequenceVersion="1" change="g.14298del">
            <Expression>NG_012340.1:g.14298del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003000.3" sequenceAccession="NM_003000" sequenceVersion="3" change="c.88del" MANESelect="true">
            <Expression>NM_003000.3:c.88del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_002991.2" sequenceAccession="NP_002991" sequenceVersion="2" change="p.Gln30fs">
            <Expression>NP_002991.2:p.Gln30fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_316" sequenceAccession="LRG_316">
            <Expression>LRG_316:g.14298del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003000.2" sequenceAccession="NM_003000" sequenceVersion="2" change="c.88delC">
            <Expression>NM_003000.2:c.88delC</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA016194" DB="ClinGen" />
        <XRef Type="rs" ID="747198089" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_003000.3(SDHB):c.88del (p.Gln30fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV000166126" Version="5">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-04-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003000.3(SDHB):c.88del (p.Gln30fs) AND Hereditary pheochromocytoma-paraganglioma" Accession="RCV000505352" Version="2">
        <ClassifiedConditionList TraitSetID="6283">
          <ClassifiedCondition DB="MedGen" ID="C1708353">Hereditary pheochromocytoma-paraganglioma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003000.3(SDHB):c.88del (p.Gln30fs) AND multiple conditions" Accession="RCV001058703" Version="5">
        <ClassifiedConditionList TraitSetID="23696">
          <ClassifiedCondition DB="MedGen" ID="C0238198">Gastrointestinal stromal tumor</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1861848">Paragangliomas 4</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0031511">Pheochromocytoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-06-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-06-17" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2016-09-24" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12618761</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19454582</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19596260</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19802898</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24395865</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25972245</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="23696" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3796" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pheochromocytoma</ElementValue>
                <XRef ID="Pheochromocytoma/5718" DB="Genetic Alliance" />
                <XRef ID="HP:0002666" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0008233" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffinoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Medullary paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin cell tumor</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">TMEM127-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">RET-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">KIF1B-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">VHL-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15105" />
                <XRef ID="15105" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHB-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHD-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C0031511" DB="MedGen" />
              <XRef ID="MONDO:0008233" DB="MONDO" />
              <XRef Type="MIM" ID="171300" DB="OMIM" />
              <XRef Type="primary" ID="HP:0002666" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="3267" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas 4</ElementValue>
                <XRef ID="Paragangliomas+4/5581" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007273" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pheochromocytoma, extraadrenal and cervical paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paragangliomas, hereditary extraadrenal</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pheochromocytoma, familial extraadrenal</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma, familial malignant</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">CAROTID BODY TUMORS AND MULTIPLE EXTRAADRENAL PHEOCHROMOCYTOMAS</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PHEOCHROMOCYTOMA/PARAGANGLIOMA SYNDROME 4</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0021" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0009" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0016" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0019" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0023" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0017" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0018" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="185470.0010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SDHB-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome (Paragangliomas 4)</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PPGL4</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PGL4</ElementValue>
                <XRef Type="MIM" ID="115310" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10546" />
                <XRef ID="10546" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2009">
                <ID Source="pmc">2668639</ID>
              </Citation>
              <Citation Type="review">
                <ID Source="PubMed">20816580</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C1861848" DB="MedGen" />
              <XRef ID="MONDO:0007273" DB="MONDO" />
              <XRef Type="MIM" ID="115310" DB="OMIM" />
            </Trait>
            <Trait ID="2160" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Gastrointestinal stromal tumor</ElementValue>
                <XRef ID="Gastrointestinal+Stromal+Tumors/2997" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011719" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gastrointestinal Stromal Sarcoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gastrointestinal stromal tumor, somatic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gastrointestinal stroma tumor</ElementValue>
                <XRef ID="HP:0100723" DB="Human Phenotype Ontology" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">GIST</ElementValue>
                <XRef Type="MIM" ID="606764" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">KIT</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8598" />
                <XRef ID="8598" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="UK NEQAS, 2012">
                <ID Source="PubMed">22685257</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGTM, 2014">
                <ID Source="PubMed">23852704</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Gastrointestinal Stromal Tumors, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Soft Tissue Sarcoma, 2024</CitationText>
              </Citation>
              <XRef ID="44890" DB="Orphanet" />
              <XRef ID="C0238198" DB="MedGen" />
              <XRef ID="D046152" DB="MeSH" />
              <XRef ID="MONDO:0011719" DB="MONDO" />
              <XRef Type="MIM" ID="606764" DB="OMIM" />
              <XRef Type="primary" ID="HP:0100723" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6283" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="9507" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hereditary pheochromocytoma-paraganglioma</ElementValue>
                <XRef ID="MONDO:0017366" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Paraganglioma-Pheochromocytoma Syndromes</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Paragangliomas and Pheochromocytomas</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PGL-PCC</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="11984" />
                <XRef ID="11984" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C1708353" DB="MedGen" />
              <XRef ID="MONDO:0017366" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="387896" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2015-03-24">
        <ClinVarSubmissionID localKey="a78833|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000216897" DateUpdated="2024-05-01" DateCreated="2015-03-24" Type="SCV" Version="8" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-04-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">25972245</ID>
          </Citation>
          <Comment>The c.88delC pathogenic mutation, located in coding exon 2 of the SDHB gene, results from a deletion of one nucleotide at position 88, causing a translational frameshift with a predicted alternate stop codon. This alteration has been identified in multiple individuals in the literature who had a personal and/or family history of PGL/PCC (Benn DE et al. J. Med. Genet. 2018 Nov;55(11):729-734; Andrews KA et al. J. Med. Genet. 2018 Jun;55(6):384-394), including a 12-year-old male diagnosed with an abdominal PGL/PCC (Benn, DE et al. Oncogene. 2003 Mar 6;22(9):1358-64), and a 13-year-old male diagnosed with 3 simultaneous extra-adrenal PGLs whose tumor showed loss of heterozygosity (LOH) at the SDHB locus (Prasad P et al. Cancer Genet Cytogenet. 2009;192(2):82-85). This mutation has also been reported in an individual diagnosed with bilateral renal carcinoma at age 27. His unaffected mother was also a carrier and there was no known family history of PGL/PCC (Paik, JY et al. J Clin Oncol. 2014 Feb 20;32(6):e10-3). Functional studies of this alteration have demonstrated the absence of SDH enzymatic activity as well as the absence of SDHB protein in cell-based assays when compared to wildtype, indicating nonsense-mediated mRNA decay or protein degradation as a mechanism for absent enzymatic activity (Kim E, Endocr. Relat. Cancer 2015 Jun; 22(3):387-97). In addition to the clinical and functional data presented in the literature, since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003000.2:c.88delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1162109" SubmissionDate="2017-07-10" DateLastUpdated="2017-09-15" DateCreated="2017-09-15">
        <ClinVarSubmissionID localKey="NM_003000.2:c.88del|MedGen:C1708353" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000599485" DateUpdated="2017-09-15" DateCreated="2017-09-15" Type="SCV" Version="1" SubmitterName="Section on Medical Neuroendocrinolgy, National Institutes of Health" OrgID="506190" OrganizationCategory="laboratory" OrgAbbreviation="SMN" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003000.2:c.88del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1708353" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB2607863</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2388769" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="4813661|MedGen:C0238198;C1861848;C0031511" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001223294" DateUpdated="2024-02-28" DateCreated="2020-04-15" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12618761</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19596260</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24395865</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19454582</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19802898</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 186518). This premature translational stop signal has been observed in individual(s) with clinical features of hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (PMID: 12618761, 19596260, 24395865). This variant is present in population databases (rs747198089, gnomAD 0.0009%). This sequence change creates a premature translational stop signal (p.Gln30Argfs*47) in the SDHB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SDHB are known to be pathogenic (PMID: 19454582, 19802898).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.17371368del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0238198" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1861848" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0031511" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2388769" TraitType="Disease" MappingType="XRef" MappingValue="C1861848" MappingRef="MedGen">
        <MedGen CUI="C1861848" Name="Paragangliomas 4" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1162109" TraitType="Disease" MappingType="XRef" MappingValue="C1708353" MappingRef="MedGen">
        <MedGen CUI="C1708353" Name="Hereditary pheochromocytoma-paraganglioma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2388769" TraitType="Disease" MappingType="XRef" MappingValue="C0238198" MappingRef="MedGen">
        <MedGen CUI="C0238198" Name="Gastrointestinal stromal tumor" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="387896" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2388769" TraitType="Disease" MappingType="XRef" MappingValue="C0031511" MappingRef="MedGen">
        <MedGen CUI="C0031511" Name="Pheochromocytoma" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

